

Human Bone Marrow-Derived Endothelial Progenitor Cells
Catalog No. :
Product Level :
Brand :
CellType :
Tissue Source :
Species :
Pack Size | Availability | Purity | Price |
---|---|---|---|
5×10⁵Cells/T25 | 1-2days |
Basic information
Notes | |
---|---|
Storage Buffer | 0.25%胰蛋白酶 |
Similar Names | |
Clone Number | |
Isotype | |
Positive Control | |
Chemical Name | Human Bone Marrow-Derived Endothelial Progenitor Cells |
Remark | |
Storage Instructions | |
Cell Name | Human Bone Marrow-Derived Endothelial Progenitor Cells |
Biological information
Growth Medium | 含FBS、生长添加剂、Penicillin、Streptomycin |
---|---|
Species Reactivity | |
Growth | 贴壁 |
Antigen Exp | |
Applications | |
Conjugation | |
Clone | |
Storage Condition | |
Gene Exp | |
Doubling Time | |
Receptor Exp | |
Immunogen | |
Host Species | |
Generation Ratio | 可传2-3代;不建议多次传代 |
Characters | 内皮细胞样 |
Security information
Culture Conditions | 气相:空气,95%;CO2,5% |
---|---|
BSL | |
Notes | |
Liquid Frequency | 每2-3天换液一次 |
Related Literature
在现代医学和生物技术迅猛发展背景下,mRNA疫苗技术的兴起,不仅标志着疫苗研发进入了一个新时代,也为传染病预防和治疗提供了全新的思路和方法。mRNA疫苗,作为一种基于核酸的疫苗,与DNA疫苗相比,具有不整合至宿主基因组的显著优势,降低了基因突变风险。此外,与已被广泛使用的蛋白质疫苗相比,mRNA疫苗的无细胞生产方式不仅加快了疫苗的研发周期,还提高了生产效率和规模化生产的可能性。mRNA疫苗能编码多种抗原,适应多样化的微生物或病毒变体,同时结合编码抗原和佐剂的双重功能,有效激发免疫反应。
Publish Date:July 8,2024
Publish Date:July 8,2024
History
Sorry, there is currently no browsing history